Susan Altschuller, Ph.D., MBA is a member of the Mural Oncology Board of Directors and serves as chair of the Audit Committee.
Dr. Altschuller has two decades of financial management, investor relations, and business planning experience with leading pharmaceutical and biotechnology companies. She has served as Cerevel’s Chief Financial Officer since May 2023. Most recently, she served as the Chief Financial Officer of ImmunoGen, a biotechnology company developing the next generation of antibody-drug conjugates for cancer patients. Before ImmunoGen, Dr. Altschuller worked at Alexion, where she was Head of Investor Relations and later, Head of Enterprise Finance. Prior to joining Alexion, Dr. Altschuller was Head of Investor Relations at Bioverativ, where she served as the primary interface with Wall Street and led all investor-related activities for the launch of the Biogen hemophilia spin-off. Early in her career, Dr. Altschuller held positions at Biogen in various functions of increasing responsibility, including investor relations, corporate finance, and commercial finance. She serves as Audit Chair on the Board of Directors of Vestaron Corporation and is a founding Board member of the HNRNP Family Foundation.
Dr. Altschuller received a BSE in Biomedical Engineering with Honors from Tulane University, a Ph.D. in Biomedical Engineering from the Illinois Institute of Technology, and an MBA from the MIT Sloan School of Management.